BioCryst Pharmaceuticals BCRX Software and Technology Licenses, Net
Software and Technology Licenses, Net at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's software and technology licenses, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's software and technology licenses, net?
- BioCryst Pharmaceuticals (BCRX) reported software and technology licenses, net of $19.7M in Q1 2026.
- How has BioCryst Pharmaceuticals's software and technology licenses, net changed year-over-year?
- BioCryst Pharmaceuticals's software and technology licenses, net increased by 306.1% year-over-year, from $4.85M to $19.7M.
- What is the long-term trend for BioCryst Pharmaceuticals's software and technology licenses, net?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's software and technology licenses, net has grown at a 8.3% compound annual growth rate (CAGR), from $3.8M to $5.67M.